Odyssean LLC Acquires 16,398 Shares of TG Therapeutics, Inc. $TGTX

Odyssean LLC lifted its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 107.5% during the 2nd quarter, Holdings Channel reports. The firm owned 31,652 shares of the biopharmaceutical company’s stock after purchasing an additional 16,398 shares during the quarter. Odyssean LLC’s holdings in TG Therapeutics were worth $1,739,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in TG Therapeutics in the second quarter valued at approximately $1,211,429,000. State Street Corp boosted its holdings in shares of TG Therapeutics by 4.7% during the 4th quarter. State Street Corp now owns 8,479,999 shares of the biopharmaceutical company’s stock worth $252,789,000 after buying an additional 379,380 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of TG Therapeutics by 35.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,051,132 shares of the biopharmaceutical company’s stock worth $61,144,000 after buying an additional 531,759 shares during the period. Pictet Asset Management Holding SA grew its position in shares of TG Therapeutics by 19.6% during the 1st quarter. Pictet Asset Management Holding SA now owns 1,747,373 shares of the biopharmaceutical company’s stock worth $58,048,000 after buying an additional 286,325 shares during the period. Finally, Invesco Ltd. increased its stake in shares of TG Therapeutics by 47.1% in the 4th quarter. Invesco Ltd. now owns 1,609,815 shares of the biopharmaceutical company’s stock valued at $47,989,000 after acquiring an additional 515,481 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. JPMorgan Chase & Co. boosted their target price on shares of TG Therapeutics from $65.00 to $72.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Bank of America lifted their price target on shares of TG Therapeutics from $17.00 to $20.00 and gave the company an “underperform” rating in a research note on Tuesday, July 7th. Zacks Research upgraded shares of TG Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, June 1st. Jefferies Financial Group reissued a “buy” rating and set a $83.00 price objective on shares of TG Therapeutics in a research report on Monday, June 22nd. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of TG Therapeutics in a research note on Wednesday, July 29th. Five research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $63.00.

TG Therapeutics Stock Down 1.3%

TG Therapeutics stock opened at $55.99 on Friday. TG Therapeutics, Inc. has a fifty-two week low of $26.76 and a fifty-two week high of $59.30. The stock has a market cap of $8.57 billion, a PE ratio of 20.43, a price-to-earnings-growth ratio of 2.43 and a beta of 1.67. The firm’s 50-day simple moving average is $53.54 and its 200 day simple moving average is $42.77. The company has a debt-to-equity ratio of 1.23, a quick ratio of 3.72 and a current ratio of 4.27.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.26). TG Therapeutics had a net margin of 55.22% and a return on equity of 73.49%. The business had revenue of $240.34 million for the quarter, compared to analysts’ expectations of $229.77 million. During the same period in the previous year, the business posted $0.17 earnings per share. The business’s revenue was up 70.2% compared to the same quarter last year. Research analysts predict that TG Therapeutics, Inc. will post 0.92 EPS for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.